Enveric Biosciences reports FY2022 net loss of $19.3M; advances EB-373 toward Phase 1 in Q4 2023

Enveric Biosciences, Inc.

2024-Q1 EPS reported -$2.31 vs consensus -$142.29 ▲ beat (+98.4%)

Comprehensive net loss $19.3M for FY2022 vs $48.8M in FY2021; diluted loss per share $13.00.
Cash and cash equivalents $17.7M, working capital $14.4M as of Dec. 31, 2022.
Lead candidate EB-373 nominated from EVM201 Series; Phase 1 trial planned for Q4 2023 in Australia.
Appointed Kevin Coveney as CFO and Lynn Gallant as VP Clinical Operations during year.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Enveric Biosciences, Inc. reported the fiscal year ended December 31, 2022 results: net income $19.3 million, EPS $13.00.

Period: the fiscal year ended December 31, 2022
Net income: $19.3 million
EPS: $13.00
Result: reported results

Exact text from the filing

Comprehensive net loss was $19.3 million for the year ended December 31, 2022, including $2.4 million in net non-cash expenses, with a basic and diluted loss per share of $13.00

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Enveric Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-010655

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.